vimarsana.com

Latest Breaking News On - Rodd leeds david waldman - Page 1 : vimarsana.com

Scopus BioPharma s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer

NEW YORK, Nov. 10, 2022 Scopus BioPharma Inc. , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play. | November 10, 2022

United statesRodd leeds david waldmanScopus biopharmaExchange commissionCompany formScopus biopharma incBoston conventionCrescendo communicationsExhibition centerAnnual meetingScopus biopharma inc stock exchangePress releaseTs scps us8091711015

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

18.10.2022 - Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet .

Marcin kortylewskiRodd leeds david waldmanScopus biopharmaJoshuar lamsteinAlan horsagerExchange commissionCompany formScopus biopharma inc nasdaqScopus biopharma incCrescendo communicationsDuet being positionedBiopharma incChief executive officerSenior scientific advisor

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors - read this article along with other careers information, tips and advice on BioSpace

United statesIsrael generalCelgene bristol myers squibbRodd leeds david waldmanScopus biopharmaJoshuar lamsteinRaphael rafi hofsteinAlan horsagerZealand pharmaDepartment of neurobiology at harvard medical schoolScopus biopharma incCrescendo communicationsWeizmann institute of scienceExchange commissionCompany formDelaware court

Scopus BioPharma s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesRodd leeds david waldmanScopus biopharmaAlan horsagerCompany formExchange commissionScopus biopharma incCrescendo communicationsChief executive officerBifunctional approachTargeting therapies summitNovel methodsDuet platformBiopharma incGlobe newswire

Scopus BioPharma s Subsidiary — Duet BioTherapeutics — to

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present onTLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to.

United statesRodd leeds david waldmanScopus biopharmaAlan horsagerCompany formExchange commissionScopus biopharma incCrescendo communicationsChief executive officerBifunctional approachTargeting therapies summitNovel methodsDuet platformBiopharma incNasdaq scpsScopus biopharma inc

vimarsana © 2020. All Rights Reserved.